Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215035 | 0.79 | ALDH1A1 (0.59) | CYP1B1ALDH1A1HSD17B10CHRM5CHRM1 | |
| SCHEMBL4625520 | 0.79 | ALDH1A1 (0.69) | CYP1B1ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL3326448 | 0.75 | ALDH1A1 (0.65) | CYP1B1ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL28154192 | 0.73 | CES1 (0.60) | ALDH1A1KMT2AMEN1HSD17B10CHRM5 | |
| SCHEMBL28154104 | 0.73 | CYP1B1 (0.47) | CYP1B1ALDH1A1BRD4HSD17B10NPSR1 | |
| SCHEMBL961634 | 0.72 | LMNA (0.53) | ALDH1A1KMT2AMEN1LMNACHRM5 | |
| SCHEMBL3860379 | 0.70 | CA2 (0.56) | ALDH1A1KMT2AMEN1CHRM5CHRM1 | |
| SCHEMBL23145007 | 0.70 | CES1 (0.38) | CYP1B1ALDH1A1CHRM5CHRM1CHRM3 | |
| SCHEMBL29811809 | 0.70 | CES1 (0.38) | CYP1B1ALDH1A1CHRM5CHRM1CHRM3 | |
| SCHEMBL2998053 | 0.70 | MEN1 (0.48) | ALDH1A1KMT2AMEN1PKMBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241834-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-11-08 | — | — | EP | disclosed |
| CN-103664973-B | Spiro-oxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-102256983-B | Spirooxindole compounds and their use as therapeutic agents | 泽农医药公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-105218565-A | Spiral shell oxindole compounds and the purposes as therapeutical agent thereof | XENON PHARMACEUTICALS INC | 2016-01-06 | — | — | CN | disclosed |
| CN-105175433-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-12-23 | — | — | CN | disclosed |
| CN-102153562-B | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| EP-2428515-B9 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-09-17 | — | — | EP | disclosed |
| EP-2752417-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2014-07-09 | — | — | EP | disclosed |
| EP-2428515-B1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-8466188-B2 | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-06-18 | — | — | US | disclosed |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CYP1B1 2518/4885ALDH1A1 1136/4885KMT2A 4075/4885 |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CYP1B1 853/4885ALDH1A1 838/4885KMT2A 2666/4885 |
| US-20100130487-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CYP1B1 853/4885ALDH1A1 838/4885KMT2A 2666/4885 |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | CYP1B1 546/4885ALDH1A1 1202/4885KMT2A 1139/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | CYP1B1 853/4885ALDH1A1 838/4885KMT2A 2666/4885 |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CYP1B1 853/4885ALDH1A1 838/4885KMT2A 2666/4885 |
| US-20100173967-A1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | CYP1B1 546/4885ALDH1A1 1202/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.